How good are we at predicting the fate of someone with acute myeloid leukaemia?

Progress toward less toxic conditioning

(2016) R. H. Buckley   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Prediction models need appropriate internal, internal–external, and external validation

(2016) Ewout W. Steyerberg et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

(2016) M Othus et al.   LEUKEMIA

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

(2016) M Othus et al.   LEUKEMIA

Acute myeloid leukemia therapy and the chosen people

(2016) E Estey et al.   LEUKEMIA

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

(2016) T Büchner et al.   LEUKEMIA

A 17-gene stemness score for rapid determination of risk in acute leukaemia

(2016) Stanley W. K. Ng et al.   NATURE

Tolerating Uncertainty — The Next Medical Revolution?

(2016) Arabella L. Simpkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bayesian predictive modeling for genomic based personalized treatment selection

(2015) Junsheng Ma et al.   BIOMETRICS

FXa variants advance toward a therapy for bleeding

(2015) J. Emsley   BLOOD

The Role of Physicians in the Era of Predictive Analytics

(2015) Allan D. Sniderman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluating Discrimination of Risk Prediction Models

(2015) Michael J. Pencina et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker: Predictive or Prognostic?

(2015) Karla V. Ballman   JOURNAL OF CLINICAL ONCOLOGY

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Low platelet count reduces subsequent complete remission rate despite marrow with

(2015) X Chen et al.   LEUKEMIA

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

(2015) R B Walter et al.   LEUKEMIA

Net Reclassification Improvement: Computation, Interpretation, and Controversies

(2014) Maarten J.G. Leening et al.   ANNALS OF INTERNAL MEDICINE

Does the Net Reclassification Improvement Help Us Evaluate Models and Markers?

(2014) Andrew J. Vickers et al.   ANNALS OF INTERNAL MEDICINE

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

(2010) Utz Krug et al.   LANCET

Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia

(2008) Alison Gardner et al.   JOURNAL OF CLINICAL ONCOLOGY